Latest news and research on all cancers and treatments, updated several times a week, plus 10,000-item data base of these
Kite Pharma focuses on developing innovative cancer immunotherapy products, emphasizing mainly on engineered autologous T cell therapy ...
In July, an experimental CAR therapy, CTL019, became the first cancer immunotherapy to receive the FDA's “breakthrough therapy” designation, after ...
Eltrapuldencel-T is the Company's patient-specific targeted cancer immunotherapy under investigation for the treatment of Stage IV or recurrent Stage ...
Four cups daily would be most protective against malignant melanoma, study finds
Malignant melanoma is the most deadly form of skin cancer
Usually starts in mole and is triggered by short, sharp bursts of sunlight
US government scientists track 450,000 men and women for a decade
A new category of medicine that scientists have been looking into, called immunotherapy, is adding years to the lives of cancer patients.
Kite Pharma's (NASDAQ:KITE) focus is on evolving innovative immunotherapy products for cancer. The company makes use of the engineered eACT ...
Current cancer treatment focuses on killing tumor cells to stop them from spreading throughout the body, but now researchers say they have found a ...
In a phase 2 trial, median survival was 5.2 months for patients with refractory metastatic pancreatic cancer treated with MM-398 (Br J Cancer.
During a retrospective study of 182 patients with nonresectable pancreatic cancer, a negative association was found between baseline circulating ...
BERKELEY, CA, USA I January 20, 2015 I Ad ur o Biotech, Inc. today announced that seven pancreatic cancer patients treated with its combination ...
So far in the clinical trial at the Institute for Cancer Research and Royal ... in relation to treating prostate and pancreatic cancer as well as liver tumours.
In addition MM-398 received Fast Track Designation for post-gemcitabine metastatic pancreatic cancer from the US FDA in November 2014.
Instead, the therapy may benefit from the activity of the immune system operating in tandem, creating a synergistic, cancer-killing effect. The work ...
It is a form of immunotherapy, which works by boosting the body's immune system, so it can then attack the cancer-causing protein in the patient's body ...
... called immunotherapy, is adding years to the lives of cancer patients. ... It works by using certain parts of an individuals immune system to fight off a ...
Anti-PD-1 Drug Improves Survival in NSCLC, Trial Halted
A study of nivolumab compared with docetaxel in patients with squamous cell NSCLC was stopped early after an analysis showed superiority of the study drug.
A study of nivolumab compared with docetaxel in patients with squamous cell NSCLC was stopped early after an analysis showed superiority of the study drug.
Multiple Biopsies Increases Cervical Cancer Precursor Detection
Multiple lesion-directed biopsies can drastically improve the sensitivity of colposcopy in women referred for abnormal cervical cancer screening.
Multiple lesion-directed biopsies can drastically improve the sensitivity of colposcopy in women referred for abnormal cervical cancer screening.
Adding RT to ADT Benefits Older Prostate Cancer Patients
Older men who received radiotherapy in addition to ADT had fewer deaths from their locally advanced prostate cancer compared with those treated with ADT alone.
Older men who received radiotherapy in addition to ADT had fewer deaths from their locally advanced prostate cancer compared with those treated with ADT alone.
Linifanib With Chemotherapy Improves PFS in NSCLC
Adding linifanib to a carboplatin/paclitaxel regimen improved progression-free survival over placebo in advanced non-squamous NSCLC patients.
Adding linifanib to a carboplatin/paclitaxel regimen improved progression-free survival over placebo in advanced non-squamous NSCLC patients.
Fertility Preservation Possible in Rare Ovarian Tumors
Women with bilateral malignant ovarian germ cells tumors may still have a good prognosis and may be able to maintain fertility with conservative treatment.
Women with bilateral malignant ovarian germ cells tumors may still have a good prognosis and may be able to maintain fertility with conservative treatment.
Higher Bortezomib Dose Upped Multiple Myeloma Survival
A new trial reported improved overall survival in myeloma patients who received a higher bortezomib dose as part of a bortezomib/melphalan/prednisone regimen.
A new trial reported improved overall survival in myeloma patients who received a higher bortezomib dose as part of a bortezomib/melphalan/prednisone regimen.
Prostate Cancer Patients Find Support in Group Fitness Classes
Group exercise programs can improve the physical and mental well-being of prostate cancer patients, as well as providing emotional and social support.
Group exercise programs can improve the physical and mental well-being of prostate cancer patients, as well as providing emotional and social support.
INTERIM Confirms 5-Year Efficacy of Intermittent Imatinib in CML
Long-term follow-up confirmed the previously reported result that intermittent administration of imatinib is safe and effective in CML patients.
Long-term follow-up confirmed the previously reported result that intermittent administration of imatinib is safe and effective in CML patients.
Ponatinib Shows Promise in CML Even After Early Trial Termination
Despite the early trial termination due to safety concerns, an analysis suggests that ponatinib offers improved efficacy over imatinib in newly diagnosed CML.
Despite the early trial termination due to safety concerns, an analysis suggests that ponatinib offers improved efficacy over imatinib in newly diagnosed CML.
Adding Erlotinib in HCC Fails to Improve Outcomes
In a phase III trial, erlotinib performed no better than placebo when added to sorafenib in treatment-naive patients with advanced hepatocellular carcinoma.
In a phase III trial, erlotinib performed no better than placebo when added to sorafenib in treatment-naive patients with advanced hepatocellular carcinoma.
Can Testosterone Treat Prostate Cancer?
A small study found that testosterone may suppress the growth of some advanced prostate cancers and could reverse resistance to testosterone-blocking agents.
A small study found that testosterone may suppress the growth of some advanced prostate cancers and could reverse resistance to testosterone-blocking agents.
Smoking Not a Risk Factor for Multiple Myeloma
Cigarette smoking is not a risk factor for multiple myeloma, according to the results of a pooled analysis of nine case-control studies.
Cigarette smoking is not a risk factor for multiple myeloma, according to the results of a pooled analysis of nine case-control studies.
ONS: Start Palliative Care at Diagnosis for All Cancer Patients
ONS has released a position paper on palliative care, emphasizing its importance throughout cancer treatment and the critical role of nurses.
ONS has released a position paper on palliative care, emphasizing its importance throughout cancer treatment and the critical role of nurses.
RT Fails to Improve on Chemo in Resected Gastric Cancer
Adding radiotherapy to adjuvant chemotherapy in the ARTIST trial yielded similar results to chemo alone in patients with D2 lymph node-resected gastric cancer.
Adding radiotherapy to adjuvant chemotherapy in the ARTIST trial yielded similar results to chemo alone in patients with D2 lymph node-resected gastric cancer.
Cancer News in Science Daily
In patients likely to have surgery, close, active monitoring of small renal tumors confined to the kidneys is associated with low rates of tumor growth or death, scientists say. The incidence of kidney cancer in the United States has been increasing for two decades, with the trend partly attributed to the introduction of abdominal imaging studies such as CT scans or MRIs in the 1980's. However, death rates due to renal cell carcinoma (kidney cancer) have not decreased, indicating that surgery may be of little or no benefit to some patients.
While not superior to capecitabine, eribulin is an active and well-tolerated therapy in women with metastatic breast cancer (MBC) receiving this therapy as a first, second, or third line chemotherapy regimen, researchers say.
A team of investigators has made key new findings about an extremely rare childhood cancer called neurocutaneous melanocytosis. This malignant cancer is characterized by an excessive growth of melanin-producing cells in both the skin and the brain. The study's authors found potential drug targets for the disease by using a molecular analysis of patient tumor cells grown in animal models.
Mutated atrx gene linked to brain and pancreatic neuroendocrine tumors is potential biomarker for rare adrenal tumors too
For the first time, researchers have found that a mutation in the ATRX gene may serve as a much-needed biomarker for the pheochromocytomas and paragangliomas that become malignant. These rare neuroendocrine tumors are typically benign, but when they go rogue, they become very aggressive.
Both epidemiological and pre-clinical studies have suggested that coffee consumption has a protective effect against non-melanoma skin cancers. However the protective effect for cutaneous melanoma (malignant and in situ) is less clear, according to a new study.
Tambahkan Komentar